Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 21, Issue 12, 2003, Pages 2335-2341

  Last, Kim W ^a   Cornelius, Victoria ^a   Delves, Trevor ^a   Sieniawska, Christine ^a   Fitzgibbon, Jude ^a   Norton, Andrew ^a   Amess, John ^a   Wilson, Andy ^a   Rohatiner, Ama Z S ^a   Lister, T Andrew ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; SELENIUM; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHOP PROTOCOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; MACOP B PROTOCOL; MACOP-B PROTOCOL; METHOTREXATE; PREDNISONE; TUMOR MARKER; VAPEC B PROTOCOL; VAPEC-B PROTOCOL; VINCRISTINE;

AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; HAZARD RATIO; HUMAN; MASS SPECTROMETRY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT RESPONSE; ADULT; AGED; BLOOD; FEMALE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICAL MODEL; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BLEOMYCIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LEUCOVORIN; LINEAR MODELS; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SELENIUM; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 0038488104     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.145     Document Type: Article

References (37)

1. Leinfelder W, Zehelein E, Mandrand-Berthelot MA, et al: Gene for a novel tRNA species that accepts L-serine and cotranslationally inserts selenocysteine. Nature 331:723-725, 1988
2. Soll D: Genetic code: Enter a new amino acid. Nature 331:662-663, 1988
3. Rayman MP: The importance of selenium to human health. Lancet 356:233-241, 2000
4. Shamberger RJ, Frost DV: Possible protective effect of selenium against human cancer. Can Med Assoc J 100:682, 1969
5. Clark LC, Cantor KP, Allaway WH: Selenium in forage crops and cancer mortality in U.S. counties. Arch Environ Health 46:37-42, 1991
6. Schrauzer GN, White DA, Schneider CJ: Cancer mortality correlation studies: III. Statistical associations with dietary selenium intakes. Bioinorg Chem 7:23-31, 1977
7. Yu SY, Zhu YJ, Li WG: Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res 56:117-124, 1997
8. Clark LC, Combs GF Jr, Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial-Nutritional Prevention of Cancer Study Group. JAMA 276:1957-1963, 1996
9. Vadgama JV, Wu Y, Shen D, et al: Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res 20:1391-1414, 2000
10. Thompson HJ, Wilson A, Lu J, et al: Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis 15:183-186, 1994
11. Caffrey PB, Frenkel GD: Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo. Cancer Chemother Pharmacol 46:74-78, 2000
12. Hu YJ, Chen Y, Zhang YQ, et al: The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res 56:331-341, 1997
13. Yoshida M, Iizuka K, Terada A, et al: Prevention of nephrotoxicity of cisplatin by repeated oral administration of ebselen in rats. Tohoku J Exp Med 191:209-220, 2000
14. Kotamraju S, Konorev EA, Joseph J, et al: Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen: Role of reactive oxygen and nitrogen species. J Biol Chem 275:33585-33592, 2000
15. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes-Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16:2780-2795, 1998
16. Deffuant C, Celerier P, Boiteau HL, et al: Serum selenium in melanoma and epidermotropic cutaneous T-cell lymphoma. Acta Derm Venereol 74:90-92, 1994
17. Avanzini P, Vinceti M, Ilariucci F, et al: Serum selenium concentrations in patients with newly diagnosed lymphoid malignancies. Haematologica 80:505-511, 1995
18. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
19. Radford JA, Whelan JS, Rohatiner AZ, et al: Weekly VAPEC-B chemotherapy for high grade non-Hodgkin's lymphoma: Results of treatment in 184 patients. Ann Oncol 5:147-151, 1994
20. McKelvey EM, Gottlieb JA, Wilson HE, et al: Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493, 1976
21. Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596-602, 1985
22. Delves HT, Sieniawska C: Simple method for the accurate determination of selenium in serum by using ICP-MS. J Anal At Spectrom 12:387-389, 1997
23. Matthews JN, Altman DG, Campbell MJ, et al: Analysis of serial measurements in medical research. BMJ 300:230-235, 1990
24. Dhaliwal HS, Rohatiner AZ, Gregory W, et al: Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma. Br J Cancer 68:767-774, 1993
25. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
26. Cox DR: Regression models and life tables. J R Stat Soc (B) 34:187-220, 1972
27. Lloyd B, Lloyd RS, Clayton BE: Effect of smoking, alcohol, and other factors on the selenium status of a healthy population. J Epidemiol Community Health 37:213-217, 1983
28. Rana MP, Sardar S, Chatterjee M: Selenomethionine in the inhibition of a transplantable murine lymphoma: Reflection on hepatic drug metabolizing enzymes. Tumour Biol 17:102-109, 1996
29. Kiremidjian-Schumacher L, Roy M, Wishe HI, et al: Supplementation with selenium and human immune cell functions: II. Effect on cytotoxic lymphocytes and natural killer cells. Biol Trace Elem Res 41:115-127, 1994
30. Roy M, Kiremidjian-Schumacher L, Wishe HI, et al: Supplementation with selenium and human immune cell functions: I. Effect on lymphocyte proliferation and interleukin 2 receptor expression. Biol Trace Elem Res 41:103-114, 1994
31. Nichol C, Herdman J, Sattar N, et al: Changes in the concentrations of plasma selenium and selenoproteins after minor elective surgery: Further evidence for a negative acute phase response? Clin Chem 44:1764-1766, 1998
32. 3) therapy]. Z Gesamte Inn Med 46:145-149, 1991
33. Kuklinski B, Zimmermann T, Schweder R: [Decreasing mortality in acute pancreatitis with sodium selenite: Clinical results of 4 years antioxidant therapy]. Med Klin 90:36-41, 1995 (suppl 1)
34. Alaejos MS, Diaz Romero FJ, Diaz Romero C: Selenium and cancer: Some nutritional aspects. Nutrition 16:376-383, 2000
35. Joint Food Safety and Standards Group: Food Surveillance Information Sheet 126. London, United Kingdom. Dietary intake of selenium. Ministry of Agriculture, Fisheries and Food, 1997
36. Joint Food Safety and Standards Group: Food Surveillance Information Sheet 191. London, United Kingdom. 1997 Total diet study-Aluminum, arsenic, cadmium, chromium, copper lead, mercury, nickel, selenium, tin and zinc. Ministry of Agriculture, Fisheries and Food, 1999
37. Rayman MP, Clark LC: Selenium in cancer prevention, in Rousel AM, Favier A, Anderson RA (eds): Trace Elements in Man and Animals 10: Proceedings of the 10th International Symposium on Trace Elements in Man and Animals. New York, Plenum Press, 2000, pp 575-580